Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

What's Driving InMed's (INM) 22% After-Hours Surge?

InMed Pharmaceuticals Inc. (NASDAQ:INM) shares rose 21.98% in after-hours trading Wednesday, reaching $1.50.

Benzinga

Why Is Agios Pharmaceuticals Stock Sinking Today?

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.

Benzinga

Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report

A federal jury has convicted Ruthia He, the founder of the telehealth startup Done Global, for orchestrating a scheme that transformed the company into an unrestricted source for Adderall prescriptions. Prosecutors argued that this case highlighted serious abuses in online mental health care, as reported by the Wall Street Journal.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

6 Healthcare Stocks With Strong Upward Momentum

Out with the old (tech), in with the new (healthcare). After several volatile weeks, it appears a full-fledged rotation has begun with investors fleeing previously high-flying tech winners in favor of underserved healthcare stocks.

Benzinga

CSL injects $2.3b into US for valuable blood plasma

After Donald Trump threatened pharmaceutical tariffs, CSL says it will invest another $2.3 billion building a new blood plasma facility in the United States.

AAP

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock is trading higher on Tuesday, with a session volume of 45.12 million compared to the average volume of 1.171 million as per data from Benzinga Pro.

Benzinga

Judge to explain why he's approving Purdue Pharma settlement plan, which calls for $7B from Sacklers

A judge is set to explain why he's approving a plan for OxyContin maker Purdue Pharma to settle thousands of lawsuits over the toll of opioids

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

UK officials ‘working day and night’ to resolve NHS drug pricing row’

Patrick Vallance says government trying to rebuild relations with pharma industry as he outlines life sciences ambition

The Guardian - UK

Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

XenoTherapeutics Inc. and Xeno Acquisition Corp, a non-profit biotechnology company, on Friday agreed to acquire Repare Therapeutics Inc. (NASDAQ:RPTX).

Benzinga

Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs

Eli Lilly And Co (NYSE:LLY) has officially become the giant quietly moving the strings behind a large slice of the pharma ETF universe. With blockbuster revenue growth, repeated earnings beats and a pipeline that refuses to slow down, Lilly isn’t just lifting its own stock – it’s powering a growing…

Benzinga

Turmoil and tensions at FDA after dramatic exit of top drug regulator

Scramble to find replacement for George Tidmarsh shines light on dysfunction at US regulatory agency

The Guardian - US

This new eye drop could help adults with age-related vision issues

The drops specifically combat presbyopia, an age related blurry vision issue.

Axios

Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know

OxyContin maker Purdue Pharma's efforts to settle thousands of lawsuits over the toll of opioids is on the verge of approval

The Independent UK

Why Is Cidara Therapeutics (CDTX) Stock Trending Overnight?

Cidara Therapeutics Inc. (NASDAQ:CDTX) shares are trending on Friday.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'

Dave Ricks, CEO of pharmaceutical giant Eli Lilly and Co. (NYSE:LLY), delivered a scathing critique of pharmacy benefit managers (PBMs), accusing the industry’s “middle actors” of “rent taking” and creating a “terrible incentive” structure that caused insulin list prices to skyrocket.

Benzinga

FDA Names Veteran Oncologist Richard Pazdur To Lead Drug Center After Ethics Scandal Ousts George Tidmarsh

The U.S. Food and Drug Administration (FDA) has appointed Dr. Richard Pazdur as the new head of its drug center, succeeding Dr. George Tidmarsh, who was removed following an ethics complaint just months after his appointment.

Benzinga

Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India

Novo Nordisk A/S (NYSE:NVO) shares are trading higher on Tuesday. The company recently lost its bidding war for Metsera Inc (NASDAQ:MTSR).

Benzinga

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share.

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Pfizer Metsera Acquisition: What It Means for Patients and the Future of Weight Loss

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with next-generation medicines.

Benzinga

Organon Cuts 2025 Sales Outlook Despite Earnings Beat

Organon (NYSE:OGN) reported third-quarter adjusted earnings of $1.01 per share on Monday, beating the consensus estimate of 94 cents. The global healthcare company reported quarterly sales of $1.602 billion, beating the Wall Street estimate of $1.56 billion.

Benzinga

Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Nasdaq Composite gaining more than 400 points on Monday.

Benzinga

Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

The Independent UK

Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk

Benzinga

Why Is Clearmind Stock Down Today?

Shares of Clearmind Medicine Inc. (NASDAQ:CMND) are falling Friday after the clinical-stage biotech company shared a key update about its stock listing.

Benzinga

EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch

Pelthos Therapeutics Inc. (NYSE:PTHS) on Friday acquired the U.S. commercialization rights to Xepi (ozenoxacin) Cream, 1%, from Biofrontera Inc. (NASDAQ:BFRI) and Ferrer Internacional S.A.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.